Bolt Biotherapeutics, Inc.
BOLTBolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing transformative cancer treatments by leveraging its proprietary Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform.
Table of contents
Earnings
Next report
Aug 13, 2026 (In 2 weeks)Competitors
By market cap
By revenue growth
Profile
Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing transformative cancer treatments by leveraging its proprietary Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform. The company's core value proposition lies in its deep expertise in myeloid biology, using pattern recognition receptors to activate the innate immune system and eliminate tumor cells. Its technology combines tumor-targeting antibodies with immune-stimulating linker-payloads to create therapies designed to elicit durable anti-cancer responses with acceptable tolerability.
A pioneer in the ISAC field with a first-in-class claudin 18.2-targeting candidate and a proprietary platform for myeloid-directed immune activation.
Questions, answered.
- What is Bolt Biotherapeutics, Inc.'s market cap?
- Bolt Biotherapeutics, Inc. (BOLT) has a market capitalization of $7.6M and trades on NASDAQ.
- Who are Bolt Biotherapeutics, Inc.'s competitors?
- Bolt Biotherapeutics, Inc.'s key competitors include Pfizer, GT Biopharma Inc. Common Stock, Nuvation Bio Inc., and others. These companies compete in similar markets and product categories.
- Who does Bolt Biotherapeutics, Inc. partner with?
- Bolt Biotherapeutics, Inc.'s notable partners include Genmab A/S, Innovent Biologics, Toray Industries, and others.
- Where is Bolt Biotherapeutics, Inc. headquartered?
- Bolt Biotherapeutics, Inc. is headquartered in United States of America and employs approximately 100 people. It has been publicly traded since 2021.